ATIC
Bifunctional purine biosynthesis protein PURH
Protein Summary
Bifunctional enzyme that catalyzes 2 steps in purine biosynthesis. Promotes insulin receptor/INSR autophosphorylation and is involved in INSR internalization (PubMed:25687571). This gene encodes a bifunctional protein that catalyzes the last two steps of the de novo purine biosynthetic pathway. The N-terminal domain has phosphoribosylaminoimidazolecarboxamide formyltransferase activity, and the C-terminal domain has IMP cyclohydrolase activity. A mutation in this gene results in AICA-ribosiduria. [provided by RefSeq, Sep 2009]
- ENST00000236959
- ENSP00000236959
- ENSG00000138363
- ENST00000435675
- ENSP00000415935
- PURH
- PURH
- AICAR
- AICARFT
- IMPCHASE
- HEL-S-70p
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
virus perturbation | 0.88 | ||
disease perturbation | 0.83 | ||
interacting protein | 0.83 | ||
transcription factor binding site profile | 0.82 | ||
kinase perturbation | 0.81 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 264.89 (req: < 5)
Gene RIFs: 33 (req: <= 3)
Antibodies: 367 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 264.89 (req: >= 5)
Gene RIFs: 33 (req: > 3)
Antibodies: 367 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 15
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 23
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 1